Prevention of neuropsychiatric adverse effects caused by dexamethasone: insights from a placebo-controlled trial with hydrocortisone.

eiden Univeristy Medical Center (LUMC)0 个研究点目标入组 180 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

Regardless of the outcome, trial results will be submitted for publication in a peer-reviewed journal and presented at conferences.

•Cranial glioma or meningioma scheduled to undergo surgery (resection)
•- Minimal dose of peri-operative cumulative dexamethasone exposure of 24mg or more in 6 days
•- =18 years
•- Good clinical condition; KPS=70
•- Life expectancy =6 months

•- Non-native speakers of Dutch or insufficient command of the Dutch language
•- Patients that are unable to overview consequences of trial participation
•- Patients with severe aphasia
•- Patients that are not able to fill in the questionnaires because of cognitive impairments at the discretion of the physician
•- Patients with psychiatric diseases or neurological deficits that interfere with the study to the judgement of treating physician

发起方

eiden Univeristy Medical Center (LUMC)